200 asymptomatic blood donors identified as anti-HTLV-III positive during routine donor screening by the Washington Red Cross and Department of Transfusion Medicine, NIH will be enrolled in a long-term prospective follow-up. In addition, there will be 100 controls consisting of blood donors who have false positive tests for anti-HTLV-III (ELISA positive, but not confirmed by Western blot). Each group of donors will: 1) be evaluated for clinical evidence of AIDS or AIDS-related disorders; 2) have extensive evaluation for AIDS-related risk factors; 3) have the specificity of their anti-HTLV-III antibody determined by confirmatory tests and Western blot analysis; 4) be cultured for the HTLV-III virus; 5) have an extensive immunologic evaluation for AIDS-related immune defects; 6) be tested for HTLV-III antigens. Donors will be followed and retested every 6 months for at least 5 years. Donors who develop evidence of AIDS will be offered evaluation and possible treatment in other NIH AIDS protocols.

Agency
National Institute of Health (NIH)
Institute
Clinical Center (CLC)
Type
Intramural Research (Z01)
Project #
1Z01CL002040-02
Application #
3963133
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
2
Fiscal Year
1986
Total Cost
Indirect Cost
Name
Clinical Center
Department
Type
DUNS #
City
State
Country
United States
Zip Code